Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Tumor eradication in mice prompts trials for human cancer vaccine
Researchers at the University of Florida College of Medicine say mRNA technology could "educate" the immune system to identify and attack cancer anywhere in the body. A promising proof-of-concept study using mice was published in Nature Biomedical Engineering.
DOJ accuses doctor of illegally prescribing opiates in exchange for sex
Ritesh Kalra, MD, allegedly wrote 31,000 opioid prescriptions between 2019 and 2025, many of which were illegitimate. He is accused of inappropriately touching patients in exchange for oxycodone scripts as part of a five-count criminal indictment.
Assembly issue spurs FDA recall on manual resuscitators
A problem with the B/V filters on SunMed adult resuscitators can cause the devices to malfunction. Due to the high safety risk this poses to patients, the FDA has assigned this recall its most serious designation.
New data highlight how Heartflow's AI software drives major shifts in heart care
One of the study's most significant findings was that patients managed using the advanced AI software saw LDL cholesterol drops of 18.7 mg/dL, with a 15% reduction in their risk of a cardiac event. Even patients with no calcified plaque saw significant changes in care management.
First patient treated with BASILICA before valve-in-valve TAVR in a mechanically-expanded valve
A heart team chose to perform BASILICA before valve-in-valve TAVR in a failed Lotus device to help minimize the risk of complications. These scenarios will likely grow more and more common as patients outlive their TAVR valves.

Boston Scientific's Sentinel Cerebral Protection System during a TAVR procedure

Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference

Cerebral embolic protection devices are proven to work. However, according to one cardiologist, they are still not consistently reducing stroke rates.

Major association of physicians presents itself as a go-to alternative vs. the government on vaccine expertise

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations.

The first Black American College of Cardiology (ACC) president Kim Allan Williams, Sr., MD, MACC, MASNC, FAHA, FESC, chair, department of medicine, University of Louisville School of Medicine, explains the impact of Trump administration restrictions on diversity equity and inclusion (DEI) on healthcare programs and clinical trials that address women, minority and low-income patients.

How anti-DEI healthcare policies are impacting patient care

All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed

Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.

FDA finalizes new heart warnings for COVID-19 vaccines

The new warnings, first proposed to Pfizer and Moderna in April, are now officially required by the FDA. They provide additional information about the potential risks of myocarditis and/or pericarditis associated with these vaccines.

How the shape, size and location of calcified carotid plaques affect stroke risk

A new analysis provides further insight into factors affecting plaque stability and subsequent ischemic events

New report raises questions about data that helped heart drug gain FDA approval

Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.

Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

Clinical

Tumor eradication in mice prompts trials for human cancer vaccine

DOJ accuses doctor of illegally prescribing opiates in exchange for sex

Assembly issue spurs FDA recall on manual resuscitators

New data highlight how Heartflow's AI software drives major shifts in heart care

First patient treated with BASILICA before valve-in-valve TAVR in a mechanically-expanded valve